All In MedTech

Device Trial Radar · NCT00307073

Adapta Pacing System Clinical Study

Adapta Clinical Study to Evaluate the Overall System Safety and Clinical Performance of the Adapta Pacing System

Last checked: Nov 20, 2026Latest source record: Oct 12, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

May 2005

Primary completion

Not stated

Study completion Nov 2005

Sponsor

Sponsor type
Industry
First posted
Mar 27, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pacemakers are implantable devices that pace (electrically stimulate) the heart. Some pacemakers have special programs to treat irregular atrial rhythms(top chambers of the heart beat too fast or too slow). Advances in pacemaker technology in recent years include features that automatically adapt to patient conditions without intervention from the clinician. Adapta (Model #ADDR01) is a new pacemaker that is designed to provide further automaticity advances by including the managed ventricular pacing (MVP) feature designed to promote intrinsic conduction (natural flow of electricity in the heart) by reducing unnecessary ventricular (lower chamber of the heart) pacing (electrical impulses). Adapta also contains a feature called TherapyGuide that is designed to allow the user to select certain conditions for each subject and receive a list of suggested pacemaker parameter value changes based on those conditions. The purpose of this study is to evaluate the overall system safety and clinical performance of the Adapta pacing system.

Conditions

  • Pacemaker
  • Bradycardia

Interventions

  • Implantable Pulse GeneratorDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from adverse device effects

Locations

7 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Graz, Austria

  • Site not named

    Prague, Czechia

  • Site not named

    Bad Nauheim, Germany

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.